Completed PHASE1 INTERVENTIONAL 2-arm NCT00981669

Rotavirus Vaccine Produced by Butantan Institute

Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immunogenicity Evaluation

Sponsor: Butantan Institute

Conditions Rotavirus Infections

Interventions placebo rotavirus vaccine

Updated 9 times since 2017 Last updated: Mar 15, 2013 Started: Mar 31, 2009 Primary completion: Mar 31, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Rotavirus Infections and is currently completed. Butantan Institute leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Butantan Institute

Data source: Butantan Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil